Sibylle Loibl

Summary

Affiliation: Frankfurt am Main
Country: Germany

Publications

  1. ncbi request reprint The role of early expression of inducible nitric oxide synthase in human breast cancer
    Sibylle Loibl
    Department of Gynaecology and Obstetrics, J W Goethe University of Frankfurt, Theodor Stern Kai 7 9, 60590 Frankfurt am Main, Germany
    Eur J Cancer 41:265-71. 2005
  2. ncbi request reprint Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study
    S Loibl
    Department of Obstetrics and Gynecology, University Hospital Frankfurt am Main, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Ann Oncol 18:689-93. 2007
  3. ncbi request reprint Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial
    Sibylle Loibl
    Department of Obstetrics and Gynecology, J W Goethe University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany
    Ann Surg Oncol 13:1434-42. 2006
  4. ncbi request reprint Breast carcinoma during pregnancy. International recommendations from an expert meeting
    Sibylle Loibl
    Department of Obstetrics and Gynaecology, J W Goethe University, Frankfurt am Main, Germany
    Cancer 106:237-46. 2006
  5. ncbi request reprint Investigations on the inducible and endothelial nitric oxide synthases in human breast cancer cell line MCF-7 - estrogen has an influence on e-NOS, but not on i-NOS
    Sibylle Loibl
    Department of Gynecology and Obstetrics, University of Frankfurt, Theodor Stern Kai 7 9, 60590 Frankfurt am Main, Germany
    Pathol Res Pract 202:1-7. 2006
  6. ncbi request reprint Immunohistochemical evaluation of endothelial nitric oxide synthase expression in primary breast cancer
    S Loibl
    Department of Gynaecology and Obstetrics, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Breast 14:230-5. 2005
  7. ncbi request reprint [Reproduction after breast cancer: what advice do we have for our patients?]
    S Loibl
    Klinikum der J W Goethe Universitat, Klinik fur Gynakologie und Geburtshilfe
    Zentralbl Gynakol 127:120-4. 2005
  8. ncbi request reprint Mitomycin C, 5-fluorouracil and folinic acid (Mi-Fu-Fo) as salvage chemotherapy in breast cancer patients with liver metastases and impaired hepatic function: a phase II study
    S Loibl
    JW Goethe University Hospital Frankfurt, Department of Obstetrics and Gynecology, Frankfurt am Main, Germany
    Anticancer Drugs 15:719-24. 2004
  9. ncbi request reprint [New aspects of carcinoma of the breast therapy and of gynaecological carcinoma treatment]
    S Loibl
    Universitätsfrauenklinik Frankfurt am Main, Germany
    Zentralbl Gynakol 125:346-52. 2003
  10. ncbi request reprint [PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients]
    S Loibl
    Klinik fur Gynakologie und Geburtshilfe, J W Goethe Universitat, Frankfurt, Germany
    Zentralbl Gynakol 128:330-5. 2006

Detail Information

Publications45

  1. ncbi request reprint The role of early expression of inducible nitric oxide synthase in human breast cancer
    Sibylle Loibl
    Department of Gynaecology and Obstetrics, J W Goethe University of Frankfurt, Theodor Stern Kai 7 9, 60590 Frankfurt am Main, Germany
    Eur J Cancer 41:265-71. 2005
    ..8% versus 67.1%; P=0.049; log-rank test). To date, this is the largest analysis of i-NOS expression in breast cancer patients and the only study to assess survival...
  2. ncbi request reprint Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study
    S Loibl
    Department of Obstetrics and Gynecology, University Hospital Frankfurt am Main, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Ann Oncol 18:689-93. 2007
    ..Classical hormone replacement therapy for hot flashes is contraindicated in breast cancer especially in endocrine responsive disease...
  3. ncbi request reprint Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial
    Sibylle Loibl
    Department of Obstetrics and Gynecology, J W Goethe University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany
    Ann Surg Oncol 13:1434-42. 2006
    ..Neoadjuvant chemotherapy can increase the rate of breast-conserving surgery in patients with operable breast cancer. However, uncertainty remains regarding surgical procedures and predictors for successful breast-conserving surgery...
  4. ncbi request reprint Breast carcinoma during pregnancy. International recommendations from an expert meeting
    Sibylle Loibl
    Department of Obstetrics and Gynaecology, J W Goethe University, Frankfurt am Main, Germany
    Cancer 106:237-46. 2006
    ..Breast carcinoma during pregnancy (BCP) is a difficult clinical situation, as it appears to put the health of the mother in conflict with that of the fetus...
  5. ncbi request reprint Investigations on the inducible and endothelial nitric oxide synthases in human breast cancer cell line MCF-7 - estrogen has an influence on e-NOS, but not on i-NOS
    Sibylle Loibl
    Department of Gynecology and Obstetrics, University of Frankfurt, Theodor Stern Kai 7 9, 60590 Frankfurt am Main, Germany
    Pathol Res Pract 202:1-7. 2006
    ..In conclusion, e-NOS and i-NOS are weakly expressed in the MCF-7 cell line, but are stimulated differently. The MCF-7 cell may contain both a constitutive NOS and an inducible NOS...
  6. ncbi request reprint Immunohistochemical evaluation of endothelial nitric oxide synthase expression in primary breast cancer
    S Loibl
    Department of Gynaecology and Obstetrics, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Breast 14:230-5. 2005
    ..A positive correlation of e-NOS with the hormone receptor status was found (P=0.031). However, no impact on survival rates was observed...
  7. ncbi request reprint [Reproduction after breast cancer: what advice do we have for our patients?]
    S Loibl
    Klinikum der J W Goethe Universitat, Klinik fur Gynakologie und Geburtshilfe
    Zentralbl Gynakol 127:120-4. 2005
    ..There is no increased risk for relapse if a breast cancer patient becomes pregnant. However, the timing of the pregnancy has not yet been fixed. It depends on the prognosis, the age, the personal situation and personal preferences...
  8. ncbi request reprint Mitomycin C, 5-fluorouracil and folinic acid (Mi-Fu-Fo) as salvage chemotherapy in breast cancer patients with liver metastases and impaired hepatic function: a phase II study
    S Loibl
    JW Goethe University Hospital Frankfurt, Department of Obstetrics and Gynecology, Frankfurt am Main, Germany
    Anticancer Drugs 15:719-24. 2004
    ..0 months and in the group of responding patients 12.0 months. Mi-Fu-Fo, therefore, provides a valid option for breast cancer patients with liver dysfunction due to liver metastases...
  9. ncbi request reprint [New aspects of carcinoma of the breast therapy and of gynaecological carcinoma treatment]
    S Loibl
    Universitätsfrauenklinik Frankfurt am Main, Germany
    Zentralbl Gynakol 125:346-52. 2003
    ..Primary and recurrent ovarian cancer therapy needs to be improved further. The optimal primary therapy for endometrial cancer and cervical cancer with radiotherapy and/or chemotherapy was another addressed issue...
  10. ncbi request reprint [PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients]
    S Loibl
    Klinik fur Gynakologie und Geburtshilfe, J W Goethe Universitat, Frankfurt, Germany
    Zentralbl Gynakol 128:330-5. 2006
    ..Bone metastases belong to the most frequent metastases in breast cancer. Currently there exist no serum markers which allow early detection of bone metastases...
  11. ncbi request reprint Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy
    Sibylle Loibl
    Department of Gynecology and Obstetrics, University of Frankfurt, Frankfurt am Main, Germany
    Cancer 95:1191-8. 2002
    ..An increased NO concentration catalyzed by NO synthase (NOS) is cytotoxic and can promote apoptosis. The expression of endothelial NOS (e-NOS) and induced NOS (i-NOS) was examined in various breast tumors...
  12. ncbi request reprint [New strategies for therapy of breast cancer. San Antonio Breast Cancer Symposium, 2002]
    S Loibl
    Universitätsfrauenklinik Frankfurt am Main
    Zentralbl Gynakol 124:451-3. 2002
  13. ncbi request reprint Adjuvant hormone therapy following primary therapy for endometrial cancer
    S Loibl
    Universitatsfrauenklinik, Theodor Stern Kai 7, Frankfurt am Main, Germany
    Eur J Cancer 38:S41-3. 2002
  14. doi request reprint Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial
    Gunter von Minckwitz
    German Breast Group, Frankfurt, Germany
    J Natl Cancer Inst 100:542-51. 2008
    ..We compared the response of nonresponding patients who continued the same treatment with that of patients who switched to a well-tolerated non-cross-resistant regimen...
  15. pmc Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast
    Gunter von Minckwitz
    Dept of Gynecology and Obstetrics, Goethe University, Frankfurt am Main, Germany
    Breast Cancer Res 10:R30. 2008
    ..To investigate the predictive value of clinical and biological markers for a pathological complete remission after a preoperative dose-dense regimen of doxorubicin and docetaxel, with or without tamoxifen, in primary operable breast cancer...
  16. pmc Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials
    Sibylle Loibl
    Department of Obstetrics and Gynecology, German Breast Group, Neu Isenburg, Germany
    Breast Cancer Res 10:R77. 2008
    ..Furthermore, most physicians tend towards therapy regimens without the use of dose-dense, highly active taxane-based treatments because of a lack of data regarding toxicities of these compounds in older patients...
  17. doi request reprint Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study
    Gunter von Minckwitz
    German Breast Group, Frankfurt, Germany
    J Natl Cancer Inst 100:552-62. 2008
    ..The relationship between extended chemotherapy and pathological complete response at surgery was investigated in a clinical trial...
  18. ncbi request reprint A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93
    Manfred Kaufmann
    Universitats Frauenklinik, Theodor Stern Kai 7, 60596 Frankfurt, Germany
    Eur J Cancer 43:2351-8. 2007
    ..72-1.42, P=0.97) and 0.77 in HR-positive patients (95% CI 0.47-1.24, P=0.27). These results do not support the general use of goserelin after adjuvant chemotherapy in this group of premenopausal patients...
  19. doi request reprint Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer
    Eugen Ruckhäberle
    Department of Obstetrics and Gynecology, Goethe University Frankfurt, Theodor Stern Kai 7, 60590, Frankfurter, Germany
    J Cancer Res Clin Oncol 139:1681-9. 2013
    ..Sphingolipids play important roles in apoptosis and cell proliferation. Sphingosine kinase 1 (SphK1) expression has a prognostic impact in primary breast cancer, but its predictive value is currently unknown...
  20. ncbi request reprint EGF-R and Her2/neu overexpressing tumors: independent collectives for treatment of breast cancer by specific monoclonal antibody-therapy
    Christine Solbach
    Department of Gynecology and Obstetrics, Johann Wolfgang Goethe University, School of Medicine, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany
    J Cancer Res Clin Oncol 129:250-1. 2003
    ....
  21. ncbi request reprint Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
    Manfred Kaufmann
    Department of Obstetrics and Gynecology, J W Goethe University Hospital, Frankfurt, Germany
    J Clin Oncol 24:1940-9. 2006
    ..As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined...
  22. ncbi request reprint Use of goserelin in the treatment of breast cancer
    Achim Rody
    Department of Obstetrics and Gynecology, JW Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt, Germany
    Expert Rev Anticancer Ther 5:591-604. 2005
    ..Treatment decisions depend upon adjuvant endocrine pretreatment. Clinical data regarding ovarian protection by synchronous use of gonadotropin-releasing hormone in young breast cancer patients receiving chemotherapy are incoherent...
  23. ncbi request reprint Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells
    Birgit Spänkuch-Schmitt
    Department of Obstetrics and Gynecology, School of Medicine, JW Goethe University, Theodor Stern Kai 7, 60596 Frankfurt, Germany
    Oncogene 21:3162-71. 2002
    ..Considerable antitumor activity was observed in vivo against A549 cells. This study suggests that antisense inhibitors targeted against PLK1 at well tolerated doses may be considered as a cancer therapeutic agent...
  24. doi request reprint NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas
    Knut Engels
    Department of Pathology, University Hospital of Frankfurt, Frankfurt, Germany
    Cancer Res 68:5159-66. 2008
    ..Pharmacogenetic iNOS/survivin-targeting strategies may hence be pursued to complement current treatment modalities in EOC...
  25. pmc Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer
    Antonia Sophie Wenners
    Department of Gynecology and Obstetrics, University Medical Center Schleswig Holstein, Kiel, Germany
    PLoS ONE 7:e45826. 2012
    ..The results show that in low-risk subgroups, NGAL was found to be a predictive marker for pCR after NACT. Furthermore, NGAL could be validated as an independent prognostic factor for decreased DFS in primary human BC...
  26. ncbi request reprint Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer
    Christine Solbach
    Department of Gynecology and Obstetrics, Johann Wolfgang Goethe University, School of Medicine, Frankfurt am Main, Germany
    Int J Cancer 101:390-4. 2002
    ..On the basis of these experimental data and our EGF-R expression analysis of breast cancer specimens, we conclude that up to 15% of breast cancer patients could benefit from this monotherapy with EMD 55900...
  27. ncbi request reprint Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluo
    G von Minckwitz
    University Women s Hospital, Frankfurt, Germany
    Anticancer Drugs 16:871-7. 2005
    ..BMF caused more mucositis and leukopenias. Thus, bendamustine, when replacing cyclophosphamide in the CMF combination, can be expected to produce longer progression-free survival in first-line treatment of MBC...
  28. ncbi request reprint Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)
    Bernd Gerber
    Department of Obstetrics and Gynaecology, University of Rostock, Rostock, Germany
    Ann Surg Oncol 21:2517-24. 2014
    ..In various cancer types, bevacizumab treatment was accompanied by an increased risk of bleedings and other surgical complications. We assessed associated surgical complications...
  29. pmc Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells
    Timo Faltus
    Department of Obstetrics and Gynecology, Medical School, J W Goethe University, Theodor Stern Kai 7, Frankfurt 60590, Germany
    Neoplasia 6:786-95. 2004
    ..Our observations suggest that siRNA targeted against human HER2/neu may be valuable tools as antiproliferative agents that display activity against neoplastic cells at very low doses...
  30. ncbi request reprint Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1
    Achim Rody
    Department of Obstetrics and Gynecology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Clin Cancer Res 13:1115-22. 2007
    ..One of those genes is plexin B1, a cell-surface receptor for the semaphorin Sema4D (CD 100). However, the biological role of plexin B1 in breast cancer is largely unknown...
  31. ncbi request reprint Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
    M Kaufmann
    J W Goethe University, Frankfurt am Main, Germany
    Ann Oncol 18:1927-34. 2007
    ..As part of this effort, data published to date were critically reviewed and indications for neoadjuvant treatment were newly defined...
  32. doi request reprint VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection
    K Engels
    Department of Pathology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    J Clin Pathol 62:448-54. 2009
    ..Therefore, an analysis and evaluation of key angiogenic factors was carried out to determine their diagnostic and prognostic value in serous ovarian cancer...
  33. ncbi request reprint Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response
    A Rody
    Department of Obstetrics and Gynecology, J W Goethe University, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Breast 16:86-93. 2007
    ..017) as well as overall response (P=0.037) and clinical complete response (cCR, P=0.050). In contrast, for both TOPO IIalpha and MAPT no correlation with pCR was observed in our sample group...
  34. ncbi request reprint [San Antonio Breast Cancer Symposium -- highlights 2004]
    A Rody
    Klinik fur Gynakologie und Geburtshilfe, J W Goethe Universitat, Frankfurt, Germany
    Zentralbl Gynakol 127:59-65. 2005
    ..The morbidity of this method is low compared with conventional axillary dissection in multicenter studies. Local tumor control is an important parameter which offers a significant survival benefit in all age cohorts...
  35. ncbi request reprint [Diagnosis and therapy of breast cancer--meeting highlights ASCO 2005]
    A Rody
    Zentrum für Gynäkologie und Geburtshilfe, J W Goethe Universität Frankfurt, Frankfurt Main
    Zentralbl Gynakol 127:389-94. 2005
  36. ncbi request reprint Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures
    A Rody
    Department of Obstetrics and Gynecology, J W Goethe University, Frankfurt, Germany
    Zentralbl Gynakol 128:76-81. 2006
    ..Furthermore we evaluated the predictive significance of prognostic gene signatures as described by Sorlie, van't Veer and Ahr for response to neoadjuvant chemotherapy...
  37. ncbi request reprint The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial
    A Rody
    Department of Obstetrics and Gynecology, J W Goethe University, Frankfurt, Germany
    Breast 16:235-40. 2007
    ..6%), basal-like (30.0%) and luminal (13.6%) cluster (P=0.215). Our data suggest that the molecular tumor subtypes based on the "intrinsic gene set" can be used to predict tumor response according to NAC...
  38. ncbi request reprint [Molecular diagnostic and targeted therapy--"Barking dogs are going to bite": presentations from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta 2006]
    A Rody
    Klinik fur Gynakologie und Geburtshilfe, J W Goethe Universitat, Frankfurt am Main
    Zentralbl Gynakol 128:233-41. 2006
    ..In this year again there have been registered an increasing number of interesting contributions from Germany, which also received international attention...
  39. doi request reprint Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades
    Manfred Kaufmann
    Department of Obstetrics and Gynaecology, J W Goethe University, Frankfurt, Germany
    Arch Gynecol Obstet 288:1203-12. 2013
    ..Evidence-based medicine has helped to improve and standardise treatment of breast cancer. This review summarises the 10th Biedenkopf meeting that was held to review the advances in breast cancer understanding and treatment. ..
  40. pmc Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas
    Gunter von Minckwitz
    Department of Gynecology and Obstetrics, University Hospital Frankfurt, Germany
    Breast Cancer Res 7:R617-26. 2005
    ..Potent antitumoral activity of scFv(FRP5)-ETA against ErbB2-overexpressing tumor cells was previously demonstrated in vitro and in animal models. Here we report the first systemic application of scFv(FRP5)-ETA in human cancer patients...
  41. ncbi request reprint Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer--a multicentre, open, controlled, prospectively randomised trial
    G von Minckwitz
    Department of Gynaecology and Obstetrics, Johann Wolfgang Goethe Universitat Frankfurt Main, Germany
    Eur J Cancer 38:2265-71. 2002
    ..In patients with early endometrial cancer, adjuvant endocrine treatment did not significantly improve the outcome. However, tamoxifen did have some beneficial effects on coexisting morbidity...
  42. ncbi request reprint Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany
    F Hilpert
    Klinik fur Gynakologie und Geburtshilfe, Campus Kiel, Universitatsklinikum Schleswig Holstein, Germany
    Ann Oncol 18:282-7. 2007
    ..The purpose of the study was to evaluate first-line platinum/paclitaxel (Taxol) under phase III trial conditions in ovarian cancer (OC) patients aged >or=70 years...
  43. ncbi request reprint The role of surgery in recurrent ovarian cancer
    J Pfisterer
    Klinik fur Gynakologie und Geburtshilfe, Campus Kiel, Universitatsklinikum Schleswig Holstein, Kiel, Germany
    Int J Gynecol Cancer 15:195-8. 2005
    ..83; 95% CI: 1.16-2.88; P= 0.009). Only patients with complete resection seem to benefit from CS. This new panel of selection criteria will be evaluated in a prospective study...
  44. ncbi request reprint The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR
    J Pfisterer
    Klinik fur Gynakologie und Geburtshilfe, Campus Kiel, Universitatsklinikum Schleswig Holstein, Kiel, Germany
    Ann Oncol 17:1568-77. 2006
    ..Abagovomab is a murine anti-idiotypic antibody against the antigen CA-125 which has been shown to elicit humoral and cellular immune responses against ovarian cancer (oc)...
  45. ncbi request reprint Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: a preliminary phase II study
    Peter C Thuss-Patience
    Charite, Humboldt University Berlin, Campus Virchow Klinikum, Berlin, Germany
    Anticancer Drugs 14:549-53. 2003
    ..We conclude that despite the small number of patients, the combination of 5-FU and oxaliplatin shows promising efficacy in this heavily pretreated population...